Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Appropriate use of tocilizumab in COVID-19 infection
Şiran Keske, Süda Tekin, Bilgin Sait, et al.
International Journal of Infectious Diseases (2020) Vol. 99, pp. 338-343
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Linlin Cheng, Haolong Li, Liubing Li, et al.
Journal of Clinical Laboratory Analysis (2020) Vol. 34, Iss. 10
Open Access | Times Cited: 367
Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis
Carlos Andrés Gómez Bautista., Cheuk‐Kwan Sun, I‐Ting Tsai, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 64
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
Reza Elahi, Parsa Karami, Amir Hossein Heidary, et al.
International Immunopharmacology (2022) Vol. 105, pp. 108536-108536
Open Access | Times Cited: 44
Systemic inflammation relates to neuroaxonal damage associated with long-term cognitive dysfunction in COVID-19 patients
Harmke B. Duindam, David Mengel, Matthijs Kox, et al.
Brain Behavior and Immunity (2024) Vol. 117, pp. 510-520
Open Access | Times Cited: 9
Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
Mina Kelleni
SN Comprehensive Clinical Medicine (2021) Vol. 3, Iss. 4, pp. 919-923
Open Access | Times Cited: 48
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database
Jaykaran Charan, Siddhartha Dutta, Rimple Jeet Kaur, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 9, pp. 1125-1136
Open Access | Times Cited: 43
Elevated Levels of Pleiotropic Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are Critically Involved With the Severity and Mortality of COVID-19: An Updated Longitudinal Meta-Analysis and Systematic Review on 147 Studies
Sarah Jafrin, Md. Abdul Aziz, Mohammad Safiqul Islam
Biomarker Insights (2022) Vol. 17
Open Access | Times Cited: 28
Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis
Qi Han, Mingyue Guo, Yue Zheng, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 40
Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis
Manuel Rubio‐Rivas, Carlos G. Forero, José María Mora‐Luján, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2021) Vol. 41, Iss. 11, pp. 884-906
Open Access | Times Cited: 36
Impacto del confinamiento por COVID-19 en la calidad de vida y salud mental
Catherin L. Ballena, Luis Cabrejos, Yheraldine Dávila, et al.
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo (2021) Vol. 14, Iss. 1, pp. 87-89
Open Access | Times Cited: 32
Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics
Hyung Muk Choi, Soo Youn Moon, Hyung In Yang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1737-1737
Open Access | Times Cited: 22
What every intensivist should know about Tocilizumab
Daniel A. Hofmaenner, Pedro David Wendel‐Garcia, Christoph C. Ganter, et al.
Critical Care (2021) Vol. 25, Iss. 1
Open Access | Times Cited: 20
Stratification of COVID-19 Severity Using SeptiCyte RAPID, a Novel Host Immune Response Test
Victor Gravrand, François Mellot, Félix Ackermann, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 419-419
Open Access | Times Cited: 8
COVID-19 associated bacterial infections in intensive care unit: a case control study
Bahar Kaçmaz, Şiran Keske, Uluman Sişman, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Tocilizumab in critically ill COVID-19 patients: An observational study
Muhammad Zain Mushtaq, Saad Bin Zafar Mahmood, Aysha Almas, et al.
International Immunopharmacology (2021) Vol. 102, pp. 108384-108384
Open Access | Times Cited: 14
Sight-threatening intraocular infection in patients with COVID-19 in India
Sameera Nayak, Taraprasad Das, Deepika C Parameswarappa, et al.
Indian Journal of Ophthalmology (2021) Vol. 69, Iss. 12, pp. 3664-3664
Open Access | Times Cited: 13
Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis
Şiran Keske, Merve Akyol, Cem Tanrıöver, et al.
Infection (2023) Vol. 51, Iss. 6, pp. 1619-1628
Open Access | Times Cited: 5
Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome
Cristina Segú-Vergés, Laura Artigas, Mireia Coma, et al.
PLoS ONE (2023) Vol. 18, Iss. 2, pp. e0280677-e0280677
Open Access | Times Cited: 4
<p>Current Options in the Treatment of COVID-19: A Review</p>
Azadeh Teimury, Elahe Mahmoodi Khaledi
Risk Management and Healthcare Policy (2020) Vol. Volume 13, pp. 1999-2010
Open Access | Times Cited: 11
Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale
Nosheen Nasir, Faisal Mahmood, Kiren Habib, et al.
Cureus (2020)
Open Access | Times Cited: 10
Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study
J. Moore, Stephanie Stroever, Patricia E. Rondain, et al.
Journal of Global Infectious Diseases (2021) Vol. 13, Iss. 2, pp. 67-71
Open Access | Times Cited: 10
Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study
Pia Clara Pafundi, Raffaele Galiero, Vittorio Simeon, et al.
PLoS ONE (2021) Vol. 16, Iss. 9, pp. e0256903-e0256903
Open Access | Times Cited: 9
Unraveling the thread of uncontrolled immune response in COVID-19 and STEMI: an emerging need for knowledge sharing
César Ríos‐Navarro, Elena de Dios, María J. Forteza, et al.
AJP Heart and Circulatory Physiology (2021) Vol. 320, Iss. 6, pp. H2240-H2254
Open Access | Times Cited: 8
Early Fall in C-Reactive Protein (CRP) Level Predicts Response to Tocilizumab in Rapidly Progressing COVID-19: Experience in a Single-Arm Pakistani Center
Saba Khurshid, Neelum Rehman, Saad Ahmed, et al.
Cureus (2021)
Open Access | Times Cited: 8
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Suresh Kumar, Rosemarie de Souza, Milind Nadkar, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top